| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Gain Therapeutics Inc (NASDAQ: GANX)
GANX Technical Analysis
3
| As on 9th Jun 2023 GANX STOCK Price closed @ 4.87 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.78 & Buy for SHORT-TERM with Stoploss of 4.59 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GANXSTOCK Price
| Open | 4.79 | Change | Price | % |
| High | 4.99 | 1 Day | 0.07 | 1.46 |
| Low | 4.79 | 1 Week | 0.28 | 6.10 |
| Close | 4.87 | 1 Month | -0.07 | -1.42 |
| Volume | 78655 | 1 Year | -1.03 | -17.46 |
| 52 Week High 5.90 | 52 Week Low 2.56 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GANX Daily Charts |
GANX Intraday Charts |
Whats New @ Bazaartrend |
GANX Free Analysis |
|
|
GANX Important Levels Intraday
| RESISTANCE | 5.26 |
| RESISTANCE | 5.13 |
| RESISTANCE | 5.06 |
| RESISTANCE | 4.98 |
| SUPPORT | 4.76 |
| SUPPORT | 4.68 |
| SUPPORT | 4.61 |
| SUPPORT | 4.48 |
GANX Forecast May 2024
| 4th UP Forecast | 9.36 |
| 3rd UP Forecast | 7.92 |
| 2nd UP Forecast | 7.03 |
| 1st UP Forecast | 6.14 |
| 1st DOWN Forecast | 3.6 |
| 2nd DOWN Forecast | 2.71 |
| 3rd DOWN Forecast | 1.82 |
| 4th DOWN Forecast | 0.38 |
GANX Weekly Forecast
| 4th UP Forecast | 6.60 |
| 3rd UP Forecast | 6.05 |
| 2nd UP Forecast | 5.70 |
| 1st UP Forecast | 5.36 |
| 1st DOWN Forecast | 4.38 |
| 2nd DOWN Forecast | 4.04 |
| 3rd DOWN Forecast | 3.69 |
| 4th DOWN Forecast | 3.14 |
GANX Forecast2024
| 4th UP Forecast | 13.29 |
| 3rd UP Forecast | 10.59 |
| 2nd UP Forecast | 8.92 |
| 1st UP Forecast | 7.25 |
| 1st DOWN Forecast | 2.49 |
| 2nd DOWN Forecast | 0.82 |
| 3rd DOWN Forecast | -0.85 |
| 4th DOWN Forecast | -3.55 |
Gain Therapeutics Inc ( NASDAQ USA Symbol : GANX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GANX Business Profile
Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland. Address: 4800 Hampden Lane, Bethesda, MD, United States, 20814
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service